Skip to main content
PMC home page
Journal of Virology logoLink to Journal of Virology
. 1994 Oct;68(10):6454–6457. doi: 10.1128/jvi.68.10.6454-6457.1994

Thermal inactivation of oral polio vaccine: contribution of RNA and protein inactivation.

B Rombaut 1, B Verheyden 1, K Andries 1, A Boeyé 1
PMCID: PMC237065  PMID: 8083982

Abstract

Heating the Sabin strains of poliovirus at 42 to 45 degrees C caused inactivation, loss of native antigen, and release of the viral RNA (vRNA). The loss of virion infectivity exceeded the loss of vRNA infectivity (as measured by transfection) by roughly 2 log10. Pirodavir inhibited the loss of native antigen and RNA release and reduced the loss of virion infectivity to the same level as the loss of vRNA infectivity. Thermoinactivation thus involves an RNA and a protein component, and pirodavir protected only against the latter.

Full text

PDF
6454

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andries K., Dewindt B., De Brabander M., Stokbroekx R., Janssen P. A. In vitro activity of R 61837, a new antirhinovirus compound. Arch Virol. 1988;101(3-4):155–167. doi: 10.1007/BF01310997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Andries K., Dewindt B., Snoeks J., Willebrords R. Lack of quantitative correlation between inhibition of replication of rhinoviruses by an antiviral drug and their stabilization. Arch Virol. 1989;106(1-2):51–61. doi: 10.1007/BF01311037. [DOI] [PubMed] [Google Scholar]
  3. Andries K., Dewindt B., Snoeks J., Willebrords R., van Eemeren K., Stokbroekx R., Janssen P. A. In vitro activity of pirodavir (R 77975), a substituted phenoxy-pyridazinamine with broad-spectrum antipicornaviral activity. Antimicrob Agents Chemother. 1992 Jan;36(1):100–107. doi: 10.1128/aac.36.1.100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Andries K., Rombaut B., Dewindt B., Boeyé A. Discrepancy between infectivity and antigenicity stabilization of oral poliovirus vaccine by a capsid-binding compound. J Virol. 1994 May;68(5):3397–3400. doi: 10.1128/jvi.68.5.3397-3400.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bauer D. J., Selway J. W., Batchelor J. F., Tisdale M., Caldwell I. C., Young D. A. 4',6-Dichloroflavan (BW683C), a new anti-rhinovirus compound. Nature. 1981 Jul 23;292(5821):369–370. doi: 10.1038/292369a0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Boublik M., Drzeniek R. Structural subunits of poliovirus particles by electron microscopy. J Gen Virol. 1977 Oct;37(1):127–134. doi: 10.1099/0022-1317-37-1-127. [DOI] [PubMed] [Google Scholar]
  7. Brioen P., Sijens R. J., Vrijsen R., Rombaut B., Thomas A. A., Jackers A., Boeyé A. Hybridoma antibodies to poliovirus N and H antigen. Arch Virol. 1982;74(4):325–330. doi: 10.1007/BF01314165. [DOI] [PubMed] [Google Scholar]
  8. CHARNEY J., MACHLOWITZ R., TYTELL A. A., SAGIN J. F., SPICER D. S. The concentration and purification of poliomyelitis virus by the use of nucleic acid precipitation. Virology. 1961 Nov;15:269–280. doi: 10.1016/0042-6822(61)90358-0. [DOI] [PubMed] [Google Scholar]
  9. Chapman M. S., Minor I., Rossmann M. G., Diana G. D., Andries K. Human rhinovirus 14 complexed with antiviral compound R 61837. J Mol Biol. 1991 Feb 5;217(3):455–463. doi: 10.1016/0022-2836(91)90749-v. [DOI] [PubMed] [Google Scholar]
  10. Denoya C. D., Scodeller E. A., Vasquez C., La Torre J. L. Foot and mouth disease virus. II. Endoribonuclease activity within purified virions. Virology. 1978 Aug;89(1):67–74. doi: 10.1016/0042-6822(78)90040-5. [DOI] [PubMed] [Google Scholar]
  11. Denoya C. D., Scodeller E. A., Vasquez C., La Torre J. L. Ribonuclease activities associated with purified foot and mouth disease virus. Arch Virol. 1978;57(2):153–159. doi: 10.1007/BF01315676. [DOI] [PubMed] [Google Scholar]
  12. Dimmock N. J. Differences between the thermal inactivation of picornaviruses at "high" and "low" temperatures. Virology. 1967 Feb;31(2):338–353. doi: 10.1016/0042-6822(67)90179-1. [DOI] [PubMed] [Google Scholar]
  13. Foriers A., Rombaut B., Boeyé A. Use of high-performance size-exclusion chromatography for the separation of poliovirus and subviral particles. J Chromatogr. 1990 Jan 5;498(1):105–111. doi: 10.1016/s0021-9673(01)84239-4. [DOI] [PubMed] [Google Scholar]
  14. Hinuma Y., Katagiri S., Fukuda M., Fukushi K., Watanabe Y. Kinetic studies on the thermal degradation of purified poliovirus. Biken J. 1965 Sep;8(3):143–153. [PubMed] [Google Scholar]
  15. Ishitsuka H., Ninomiya Y. T., Ohsawa C., Fujiu M., Suhara Y. Direct and specific inactivation of rhinovirus by chalcone Ro 09-0410. Antimicrob Agents Chemother. 1982 Oct;22(4):617–621. doi: 10.1128/aac.22.4.617. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Kenny M. T., Dulworth J. K., Bargar T. M., Torney H. L., Graham M. C., Manelli A. M. In vitro antiviral activity of the 6-substituted 2-(3',4'-dichlorophenoxy)-2H-pyrano[2,3-b]pyridines MDL 20,610, MDL 20,646, and MDL 20,957. Antimicrob Agents Chemother. 1986 Sep;30(3):516–518. doi: 10.1128/aac.30.3.516. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Minor P. D., Ferguson M., Evans D. M., Almond J. W., Icenogle J. P. Antigenic structure of polioviruses of serotypes 1, 2 and 3. J Gen Virol. 1986 Jul;67(Pt 7):1283–1291. doi: 10.1099/0022-1317-67-7-1283. [DOI] [PubMed] [Google Scholar]
  18. Otto M. J., Fox M. P., Fancher M. J., Kuhrt M. F., Diana G. D., McKinlay M. A. In vitro activity of WIN 51711, a new broad-spectrum antipicornavirus drug. Antimicrob Agents Chemother. 1985 Jun;27(6):883–886. doi: 10.1128/aac.27.6.883. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Rombaut B., Andries K., Boeyé A. A comparison of WIN 51711 and R 78206 as stabilizers of poliovirus virions and procapsids. J Gen Virol. 1991 Sep;72(Pt 9):2153–2157. doi: 10.1099/0022-1317-72-9-2153. [DOI] [PubMed] [Google Scholar]
  20. Rombaut B., Foriers A., Boeyé A. Purification of poliovirus 14 S subunits by sucrose gradient ultracentrifugation and high-performance size-exclusion chromatography. J Virol Methods. 1990 Sep;29(3):303–311. doi: 10.1016/0166-0934(90)90057-m. [DOI] [PubMed] [Google Scholar]
  21. Rombaut B., Vrijsen R., Boeyé A. Stabilization by host cell components and Mg2+ of the neutralization epitopes of poliovirus. J Gen Virol. 1985 Feb;66(Pt 2):303–307. doi: 10.1099/0022-1317-66-2-303. [DOI] [PubMed] [Google Scholar]
  22. Smith T. J., Kremer M. J., Luo M., Vriend G., Arnold E., Kamer G., Rossmann M. G., McKinlay M. A., Diana G. D., Otto M. J. The site of attachment in human rhinovirus 14 for antiviral agents that inhibit uncoating. Science. 1986 Sep 19;233(4770):1286–1293. doi: 10.1126/science.3018924. [DOI] [PubMed] [Google Scholar]
  23. Tovell D. R., Colter J. S. The interaction of tritium-labelled mengo virus RNA and L cells: the effects of DMSO and DEAE-dextran. Virology. 1969 Apr;37(4):624–631. doi: 10.1016/0042-6822(69)90280-3. [DOI] [PubMed] [Google Scholar]
  24. Vrijsen R., Rombaut B., Boeyé A. A simple quantitative protein A micro-immunoprecipitation method; assay of antibodies to the N and H antigens of poliovirus. J Immunol Methods. 1983 Apr 29;59(2):217–220. doi: 10.1016/0022-1759(83)90033-9. [DOI] [PubMed] [Google Scholar]
  25. Woods M. G., Diana G. D., Rogge M. C., Otto M. J., Dutko F. J., McKinlay M. A. In vitro and in vivo activities of WIN 54954, a new broad-spectrum antipicornavirus drug. Antimicrob Agents Chemother. 1989 Dec;33(12):2069–2074. doi: 10.1128/aac.33.12.2069. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES